European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Subscribe To Our Newsletter & Stay Updated